The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

[1]  H. Rugo,et al.  Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER , 2014, British Journal of Cancer.

[2]  H. Rugo,et al.  Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[3]  G. Somlo,et al.  Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. , 2014, The oncologist.

[4]  R. Finn,et al.  Current approaches and future directions in the treatment of HER2-positive breast cancer. , 2013, Cancer treatment reviews.

[5]  H. Rugo,et al.  First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. , 2013, The oncologist.

[6]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[7]  S. Barni,et al.  A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. , 2013, Clinical breast cancer.

[8]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[9]  Amy P Abernethy,et al.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Dreyer,et al.  Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Rugo,et al.  Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study , 2012, Breast Cancer Research and Treatment.

[12]  L. Chow,et al.  New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? , 2012, Cancer treatment reviews.

[13]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[15]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Dihua Yu,et al.  Molecular predictors of response to trastuzumab and lapatinib in breast cancer , 2010, Nature Reviews Clinical Oncology.

[19]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[21]  M. Birkner,et al.  Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. , 2009 .

[22]  M. Mottolese,et al.  Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. , 2008, Breast.

[23]  David Artz,et al.  Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Joseph Lipscomb,et al.  Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Melissa L. Johnson,et al.  Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.

[26]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[27]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[28]  F. Lieberman,et al.  Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. , 2006, Seminars in oncology.

[29]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[30]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[31]  C. Cleeland,et al.  Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. , 2005, Oncology nursing forum.

[32]  M. Gawlicki,et al.  PMC28 LINGUISTIC VALIDATION OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIR , 2005 .

[33]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[35]  D S Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[39]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[40]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Sharp,et al.  The financial impact of a cancer diagnosis , 2010 .

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .